Absence: 73.1% median reduction in the number of absence seizure ≥3s, p = 0.012 DEE: 63.3% median reduction in major motor seizures REM sleep improvement in patients with Absence Seizures: mean 90% ...
Bright Minds Biosciences Inc. (DRUG) has been able to initiate its phase 2 BREAKTHROUGH study using its 5-HT2C agonist BMB-101 for the treatment of adult patients with classic Absence Epilepsy and ...
New contributions to the field of epilepsy have opened a window into the cellular events that occur in the brain during absence seizures. At first, the teacher described her six-year-old student as ...
Like many teenagers, Danielle Holton's first car was a ticket to freedom. At age 17, she bought a used Hyundai wagon from her mom, paying for it with money from her job as a certified nursing ...
The areas of the cerebral cortex that are affected in mice with absence epilepsy have been pinpointed by research that also shows that transplanting embryonic neural cells into these areas can ...
This transcript has been edited for clarity. Andrew N. Wilner, MD: Welcome to Medscape. I'm your host, Dr Andrew Wilner, reporting on the annual American Epilepsy Society meeting. With me today is my ...
Since 1983, eight new AEDs have been introduced (see Table 2 below). Sadly, a recent VA study of more than 21,000 subjects aged 65 years and older revealed that 80% were being treated with ...
The Phase 2 open-label, multicenter study evaluated safety, tolerability and efficacy of BMB-101 in adults with drug-resistant Absence Seizures and DEE. A total of 24 patients were enrolled, exceeding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results